Topiramat 1A Pharma
Topiramat 1A Pharma Uses, Dosage, Side Effects, Food Interaction and all others data.
Topiramat 1A Pharma is a sulfamate-substituted monosaccharide, related to fructose. Topiramat 1A Pharma is quickly absorbed after oral use. Topiramat 1A Pharma enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. Topiramat 1A Pharma has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particularly subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages.
Topiramat 1A Pharma prevents the occurrence of seizures and prevents migraine symptoms by reducing neural pathway excitability. It is important to note that this drug may cause metabolic acidosis, mood changes, suicidal thoughts and attempts, as well as kidney stones. When topiramate is combined with valproic acid, it is known to cause hypothermia.
| Trade Name | Topiramat 1A Pharma |
| Availability | Prescription only |
| Generic | Topiramate |
| Topiramate Other Names | Tipiramate, Tipiramato, Topiramate, Topiramato, Topiramatum |
| Related Drugs | Emgality, Trokendi XR, Reyvow, gabapentin, propranolol, clonazepam, lamotrigine, diazepam, atenolol, pregabalin |
| Type | |
| Formula | C12H21NO8S |
| Weight | Average: 339.362 Monoisotopic: 339.098787343 |
| Protein binding | Topiramate is not highly bound to plasma proteins, with an estimated plasma protein binding of 9-17% according to some studies. The FDA label indicates that the protein binding of topiramate is 15-41%. |
| Groups | Approved |
| Therapeutic Class | Adjunct anti-epileptic drugs |
| Manufacturer | |
| Available Country | Austria, Sweden |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
This drug is used to treat epilepsy in both children and adults. In children it is also used for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delay). It is now most frequently prescribed for the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder and alcoholism.
The drug is also used to treat Post Traumatic Stress Disorder. Studies suggest that Topiramat 1A Pharma is effective against infantile spasms.
Monotherapy in Epilepsy: Topiramat 1A Pharma is used for initial monotherapy in patients of 10 years of age and older with partial onset or primary generalized tonic-clonic seizures.
Adjunctive Therapyin Epilepsy: Topiramat 1A Pharma is used for adjunctive therapy for adults and pediatric patients ages 2-16 years with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.
Migraine: Topiramat 1A Pharma is used for adults for the prophylaxis of migraine headache.
Topiramat 1A Pharma is also used to associated treatment for these conditions: Alcohol Dependency, Grand mal Generalized tonic-clonic seizure, Lennox-Gastaut Syndrome (LGS), Migraine, Moods Disorders, Partial-Onset Seizures, Weight, Primary generalized tonic-clonic seizure Epilepsy, Weight Reduction
How Topiramat 1A Pharma works
A seizure is an abnormal and unregulated electrical discharge occurring in the brain. This leads to transient interruption in brain function, manifested by reduced alertness, abnormal sensations, and focal involuntary movements or convulsions. Several types of seizures exist, with common types including tonic-clonic seizures and partial onset seizures.
The exact mechanisms by which topiramate exerts pharmacological actions on seizures and migraines are currently not fully characterized. Several properties of this drug, however, are likely to contribute to its therapeutic effects. Topiramat 1A Pharma has been observed to exert actions on voltage-dependent sodium channels, GABA receptors, and glutamate receptors.
Topiramat 1A Pharma stimulates GABA-A receptor activity at brain non-benzodiazepine receptor sites and reduces glutamate activity at both AMPA and kainate receptors. Normally, GABA-A receptors are inhibitory and glutaminergic receptors are stimulatory for neuronal activity. By increasing GABA activity and inhibiting glutamate activity, topiramate blocks neuronal excitability, preventing seizures and migraines. Additionally, it blocks the voltage-dependent sodium channels, further blocking seizure activity. Topiramat 1A Pharma has been shown to inhibit various carbonic anhydrase isozymes, but the clinical significance of this is unknown at this time.
Dosage
Topiramat 1A Pharma dosage
The initial dose normally is low and increased in slow steps.The usual initial dose is 25 to 50 mg daily in 2 single doses. Recommended increments are 25 to 50 mg every 1 or 2 weeks. Common doses for maintenance treatment are 100 to 200 mg daily. The highest dose possible is 1,000 mg daily in divided doses.
Monotherapy Use: The recommended maximum dose for Topiramat 1A Pharma monotherapy in adults and children 10 years of age and older is 400 mg/day in two divided doses.
Adjunctive Therapy Use Adults (17 Years of Age and Over): The recommended total daily dose of Topiramat 1A Pharma is 400 mg/day in Partial Seizures or Primary Generalized Tonic-Clonic Seizures. Daily doses above 1600 mg have not been studied.
Pediatric Patients (Ages 2 to 16 Years): Partial Seizures or Primary Generalized Tonic-Clonic Seizures The recommended total daily dose of Topiramat 1A Pharma tablets as adjunctive therapy for patients with partial seizures or primary generalized tonic-clonic seizures is approximately 5 to 9 mg/kg/day in two divided doses.Titration should begin at 25 mg (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1 or 2 week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome.
Topiramat 1A Pharma tablets can be taken without regards to meals.
Side Effects
The most common side effects include a change in taste and feelings of pins and needles in the head and extremities. Less common side effects include cognitive deficiency (particularly word-finding difficulty); difficulty in understanding, grogginess, lethargy, renal (kidney) stones, vision abnormality, weight loss, breast pain, abdominal pain, intense sweating, menstrual disorder and dry mouth.
Toxicity
The LD50 of intraperitoneal topiramate in the rat is above 1500 mg/kg.
Overdose information
In a study of 4 healthy adult women taking topiramate, the severity of clinical effects following an overdose ranged from asymptomatic to severe, with no deaths reported. According to the FDA prescribing information for topiramate, an overdose may cause hypotension, severe metabolic acidosis, coma, abdominal pain, visual disturbances, convulsions, drowsiness, speech abnormalities, impaired mentation and coordination, stupor, agitation, dizziness, as well as depression.
In the case of a recent ingestion of topiramate, the stomach contents should be emptied through the induction of emesis or gastric lavage. Offer supportive treatment, including activated charcoal and hemodialysis.
Precaution
Concomitant administration of Topiramat 1A Pharma and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone. In patients who develop unexplained lethargy, vomiting, or changes in mental status, hyperammonemic encephalopathy should be considered and an ammonia level should be measured.
Interaction
Potential interactions between Topiramat 1A Pharma and standard AEDs like Phenytoin, Carbamazepine and Valproic acid were observed during the concomitant treatment with these drugs for antiepileptic patients. Beside these. Concomitant use of Topiramat 1A Pharma, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation. Digoxin, CNS depressants, oral contraceptives. Hydrochlorothiazide (HCTZ) may also interact with Topiramat 1A Pharma.
Food Interaction
- Avoid a ketogenic diet. This type of diet increases the risk of kidney stones.
- Take with or without food. Food slightly alters absorption but not to any clinically significant extent.
Topiramat 1A Pharma Alcohol interaction
[Moderate] GENERALLY AVOID:
Topiramat 1A Pharma, when coadministered with other CNS depressants including alcoholic beverages, may lead to excessive somnolence and other forms of nervous system depression.
The patient should be informed to avoid alcohol or to use caution if these agents are coadministered, especially if performing hazardous tasks such as driving or operating machinery.
Topiramat 1A Pharma Drug Interaction
Major: aripiprazole, diphenhydramineModerate: duloxetine, escitalopram, pregabalin, acetaminophen / hydrocodone, alprazolam, sertraline, cetirizineUnknown: amphetamine / dextroamphetamine, omega-3 polyunsaturated fatty acids, albuterol, montelukast, levothyroxine, cyanocobalamin, ascorbic acid, ergocalciferol, cholecalciferol, lisdexamfetamine, bupropion
Topiramat 1A Pharma Disease Interaction
Major: bone marrow depression/blood dyscrasias, oligohidrosis/hyperthermia, severe liver diseaseModerate: suicidal tendency, renal dysfunction, metabolic acidosis, angle closure glaucoma, hemodialysis, nephrolithiasis
Volume of Distribution
The mean apparent volume of distribution of topiramate ranges from 0.6-0.8 L/kg when doses of 100mg to 1200mg are given. Topiramat 1A Pharma readily crosses the blood-brain barrier.
Elimination Route
After a 400mg dose in one clinical trial, topiramate reached maximal concentrations within 1.8-4.3 hours and ranged from 1.73-28.7 ug/mL. Food did not significantly affect the extent of absorption, despite delaying time to peak concentration. In patients with normal creatinine clearance, steady state concentrations are reached within 4 days. The bioavailability of topiramate in tablet form is about 80% compared to a topiramate solution.
Half Life
The elimination half-life is reported to be in the range of 19-23 hours. If topiramate is given with enzyme-inducers, the half-life can be reduced to 12-15 hours because of increased metabolism.
Clearance
The mean oral plasma clearance of topiramate ranges from 22-36 mL/min while the renal clearance is 17-18 mL/min, according to one pharmacokinetic study. The FDA label for topiramate indicates a similar oral plasma clearance of approximately 20 to 30 mL/min in adults.
Elimination Route
Topiramat 1A Pharma is mainly eliminated through the kidneys. About 70-80% of the eliminated dose is found unchanged in the urine.
Pregnancy & Breastfeeding use
Topiramat 1A Pharma is pregnancy category C. So it may be given only if clearly needed and after the assessment of risk benefit ratio. It is not known whether Topiramat 1A Pharma is excreted through breast milk. So caution should be taken if it is prescribed to a breast feeding mother.
Contraindication
Topiramat 1A Pharma tablets are contraindicated in patients with a history of hypersensitivity to any component of this product.
Special Warning
Patients with Renal Impairment: In renally impaired subjects (creatinine clearance less than 70 ml/min/1.73 m2), one-half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.
Patients Undergoing Hemodialysis: Topiramat 1A Pharma is cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause Topiramat 1A Pharma concentration to fall below that required to maintain an anti-seizure effect.To avoid rapid drops in Topiramat 1A Pharma plasma concentration during hemodialysis, a supplemental dose of Topiramat 1A Pharma may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of Topiramat 1A Pharma in the patient being dialyzed.
Acute Overdose
Overdoses of Topiramat 1A Pharma includes convulsions, drowsiness, speech disturbance, blurred vision, diplopia, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression.The clinical consequences are not severe. Topiramat 1A Pharma overdose results in severe metabolic acidosis.
In acute Topiramat 1A Pharma overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of ernes is. Activated charcoal has been shown to adsorb Topiramat 1A Pharma in vitro. Hemodialysis is an effective means of removing Topiramat 1A Pharma from the body.
Storage Condition
Store at a cool & dry place, protected from light and moisture. Keep out of reach of the children.
Innovators Monograph
You find simplified version here Topiramat 1A Pharma
Topiramat 1A Pharma contains Topiramate see full prescribing information from innovator Topiramat 1A Pharma Monograph, Topiramat 1A Pharma MSDS, Topiramat 1A Pharma FDA label
FAQ
What is Topiramat 1A Pharma used for?
Topiramat 1A Pharma is a medicine used to treat epilepsy. These are also called anti-epileptic medicines. It can also be taken to prevent migraine. This medicine is only available on prescription.
How safe is Topiramat 1A Pharma?
Topiramat 1A Pharma is safe for long-term use when taken as prescribed. However, several common and potentially severe side effects have been reported by a small number of patients. There are also quite a few drugs that can cause harmful interactions or become ineffective when taken in conjunction with Topiramat 1A Pharma.
How does Topiramat 1A Pharma work?
Topiramat 1A Pharma works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.
What are the common side effects of Topiramat 1A Pharma?
Common side effects of Topiramat 1A Pharma include feeling sleepy, dizziness, diarrhoea and feeling sick. These are usually mild and go away by themselves.
Is Topiramat 1A Pharma safe during pregnancy?
If you take Topiramat 1A Pharma during pregnancy, there is a higher risk that your baby will develop a cleft lip and cleft palate. Oral clefts happen early in pregnancy, before many women even know they are pregnant.
Is Topiramat 1A Pharma safe during breastfeeding?
Topiramat 1A Pharma passes into breast milk. Babies usually have very low levels of Topiramat 1A Pharma in their systems, and side effects or harmful effects in the nursing baby are rarely reported.
Can I drink alcohol with Topiramat 1A Pharma?
Because Topiramat 1A Pharma can cause mental and psychological side effects, it's not recommended that you drink alcohol while taking Topiramat 1A Pharma.
Can I drive after taking Topiramat 1A Pharma?
Do not drive a car or operate machinery until you know how this medication affects you. if you are taking Topiramat 1A Pharma to control seizures, you should know that you may continue to have seizures during your treatment.
When is the best time to take Topiramat 1A Pharma?
You can take Topiramat 1A Pharma at any time of day, but try to take your doses at the same time each day. Try to space your doses evenly through the day. For example, first thing in the morning and in the evening. Topiramat 1A Pharma tablets can be taken with or without food.
Is Topiramat 1A Pharma safe to take long term?
Yes, many people take Topiramat 1A Pharma safely for many months or years.
What does Topiramat 1A Pharma do to the brain?
Topiramat 1A Pharma decrease abnormal excitement in the brain. Among other actions,Topiramat 1A Pharma affects the activity of the neurotransmitter gamma-aminobutyrate.
Is Topiramat 1A Pharma good for anxiety?
Topiramat 1A Pharma isn't approved to treat anxiety. However, the drug may sometimes be used off-label to treat people with certain anxiety disorders, such as obsessive-compulsive disorder.
Should I take Topiramat 1A Pharma at night or in the morning?
Topiramat 1A Pharma is usually taken with or without food once a day in the morning. Topiramat 1A Pharma may cause difficulty falling asleep or staying asleep if it is taken in the evening. Take phentermine and Topiramat 1A Pharma at around the same time every day.
Can Topiramat 1A Pharma cause a stroke?
Hypohidrosis is one of the described side effects of Topiramat 1A Pharma, and it can contribute to the development of heart stroke in patients taking this drug.
Can Topiramat 1A Pharma cause heart problems?
Topiramat 1A Pharma can increase your resting heart rate.
How fast will I lose weight on Topiramat 1A Pharma?
It can take some time to see weight loss results from taking Topiramat 1A Pharma. Some people may not notice a difference until they've taken the drug for at least four months, while other people may start to lose weight in their first month of taking it. Weight loss results from topiramate are proven to increase over time.
How long does it take Topiramat 1A Pharma to get out of my system?
Topiramat 1A Pharma stays in your system between four and six days after your last dose, depending on your personal factors such as dosage and metabolism.
Is Topiramat 1A Pharma hard on the liver?
Topiramat 1A Pharma is thought to be rarely associated with liver injury and by and large known to cause liver toxicity in conjunction with other anticonvulsants.
Is Topiramat 1A Pharma bad for my kidneys?
Topiramat 1A Pharma can increase the level of acid in your blood . This can weaken your bones, cause kidney stones, or cause growth problems in children .
Does Topiramat 1A Pharma cause chest pain?
Chest pain is a previously undocumented potential side effect of Topiramat 1A Pharma.
Is Topiramat 1A Pharma an anti inflammatory?
Topiramat 1A Pharma modulates post-infarction inflammation primarily by targeting monocytes or macrophages.
Will Topiramat 1A Pharma effect my fertility?
Topiramat 1A Pharma for 4 weeks did not have much effect on fertility.
Can I take Topiramat 1A Pharma long time ?
Topiramat 1A Pharma usually takes a couple of weeks for it to work. If taking Topiramat 1A Pharma to prevent migraines, it can take up to 3 months for it to work fully.
What happen If I stop Topiramat 1A Pharma suddenly ?
If you suddenly stop taking Topiramat 1A Pharma, you may have severe seizures, even if you have not had seizures in the past. Your doctor will probably decrease your dose gradually.
What happens if I overdose?
An overdose of topiramate can be fatal.
Overdose can cause drowsiness, agitation, depression, double vision, thinking problems, problems with speech or coordination, fainting, and seizure.
